04.08.24 -- Shocking! Biotech Facilities Don't Maintain Themselves

The pros and cons of soluble and insoluble processes: isolating, solubilizing and properly refolding, and strategies to improve the performance of IB processes.

The quality functions in biopharma manufacturing are under pressure due to regulatory and political scrutiny combined with a global market rife with complex quality standards.

This article highlights the importance of scalability and flexibility in the choice of an early-stage manufacturing strategy and how that decision impacts financial outcomes for a drug development program.

As drug discovery accelerates, so too does the need for robust cell line development. Learn how a CDMO that prioritizes R&D can help you unlock the potential for faster, more efficient development.

PCM offers a number of advantages, including streamlined development and increased flexibility. Review the key drivers for PCM as well as the hurdles that stand in the way of industry-wide adoption.

The leap from sending your RFPs to choosing a CDMO partner requires the ability to think critically about the red flags and green flags of a given proposal.

Catalent's local team in Japan provides comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, and local and global distribution.

Simtra currently has open capacity for liquid vial projects at both manufacturing sites and can support rapid tech transfer depending on the complexity of the project and the availability of materials.

Development beyond traditional mAbs is increasing, and today, we see antibody variants like multi-specific and bispecific antibodies and antibody fragments.